How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types
- 20 November 2020
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 27 (1) , 137-148
Abstract
Introduction von Willebrand disease (VWD) is the most common inherited bleeding disorder and caused by an absence, deficiency or defect in von Willebrand factor (VWF). VWD is currently classified into six different types: 1, 2A, 2B, 2N, 2M, 3. Notably, 2M VWD is more often misdiagnosed as 2A or type 1 VWD than properly identified as 2M VWD. Aim To describe an algorithmic approach to better ensure appropriate identification of 2M VWD, and reduce its misdiagnosis, as supported by sequential laboratory testing. Methods Comparative assessment of types 1, 2A, 2B and 2M VWD using various laboratory tests, including VWF antigen and several VWF activity assays, plus DDAVP challenge data, ristocetin‐induced platelet agglutination (RIPA) data, multimer analysis and genetic testing. Results Types 1, 2A, 2B and 2M VWD give characteristic test patterns that can provisionally classify patients into particular VWD types. Notably, type 1 VWD shows low levels of VWF, but VWF functional concordance (VWF activity/Ag ratios >0.6), with both baseline assessment and post‐DDAVP. Types 2A, 2B and 2M VWD show VWF functional discordance (low VWF activity/Ag ratio(s)) dependent on the defect, but type 2M separates from 2A/2B VWD based on specific test patterns, especially with collagen binding vs glycoprotein Ib binding assays. RIPA identifies 2B VWD. Multimers separate 2M from 2A/2B. Conclusion We provide strategies to improve correct diagnosis of VWD, especially focussed on 2M VWD, and which can be used by most diagnostic haemostasis laboratories, reserving genetic analysis (if required) for confirmation.Keywords
This publication has 37 references indexed in Scilit:
- Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patientsJournal of Thrombosis and Haemostasis, 2012
- von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding DisorderSeminars in Thrombosis and Hemostasis, 2011
- von Willebrand Factor Assay Proficiency TestingAmerican Journal of Clinical Pathology, 2011
- Rethinking the diagnosis of von Willebrand diseaseThrombosis Research, 2011
- The prevalence of symptomatic von Willebrand disease in primary care practiceJournal of Thrombosis and Haemostasis, 2009
- Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?Thrombosis Research, 2009
- Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttalJournal of Thrombosis and Haemostasis, 2008
- von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)1Haemophilia, 2008
- Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand FactorJournal of Thrombosis and Haemostasis, 2006
- An External Quality Assessment Program for von Willebrand Factor Laboratory Analysis: An Overview from the European Concerted Action on Thrombosis and Disabilities FoundationSeminars in Thrombosis and Hemostasis, 2006